Collgen Biotechnologies (06990.HK) has received the relevant payments from Yilin Biopharmaceuticals as part of the settlement agreement reached.

Zhithong Financial News App, Collin BioTech (06990.HK) announced that the company has reached a settlement agreement with Suzhou Yilian Biopharmaceutical Co., Ltd. (Yilian Biopharmaceutical), Dr. Xue Tongtong, Dr. Xiaoliang, and Dr. Cai Jiaqiang. According to the settlement, the company has recently received RMB 602.5 million from Yilian Biopharmaceutical as revenue sharing for YL201. As of the fiscal year 2026 and as of the date of this announcement, the company has received a total of RMB 702.7 million from Yilian Biopharmaceutical for the payments made pursuant to the settlement agreement (including the aforementioned RMB 602.5 million).